9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
88 hedge funds and large institutions have $13M invested in 9 Meters Biopharma in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 29 closing their positions.
781% more call options, than puts
Call options by funds: $476K | Put options by funds: $54K
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
13% less funds holding
Funds holding: 101 → 88 (-13)
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
71% less capital invested
Capital invested by funds: $45.2M → $13M (-$32.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.15M |
| 2 |
CWM
Curi Wealth Management
Raleigh,
North Carolina
|
+$971K |
| 3 |
Millennium Management
New York
|
+$872K |
| 4 |
E
Ergoteles
New York
|
+$469K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.42M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.23M |
| 4 |
Renaissance Technologies
New York
|
-$838K |
| 5 |
O
OrbiMed
New York
|
-$834K |
NMTR Hedge Fund Activity: Q2 2022 in Review
88 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2022, worth a combined $13M — down 71% from $45.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of NMTR and 17 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 22 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.15M. The largest seller was BlackRock, cutting an estimated $5M.
- 88 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2022, down from 101 in Q1 2022.
- Funds reported $13M of 9 Meters Biopharma stock for Q2 2022, down 71% quarter-over-quarter.
- 17 funds opened new 9 Meters Biopharma positions in Q2 2022 and 29 closed out, a net change of -12 holders.
- The largest 9 Meters Biopharma buyer in Q2 2022 was Laurion Capital Management, an estimated $2.15M added.
- The largest 9 Meters Biopharma seller in Q2 2022 was BlackRock, an estimated $5M sold.
Based on aggregated 13F filings for Q2 2022.